Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Indications and limitations of vismodegib for basal cell carcinoma--reply.

Gill HS, Moscato EE, Silkiss RZ.

JAMA Ophthalmol. 2014 Jul;132(7):906. doi: 10.1001/jamaophthalmol.2014.1805. No abstract available.

PMID:
25010181
2.

Indications and limitations of vismodegib for basal cell carcinoma.

Yin VT, Sniegowski M, Esmaeli B.

JAMA Ophthalmol. 2014 Jul;132(7):905-6. doi: 10.1001/jamaophthalmol.2014.1787. No abstract available.

PMID:
25010179
3.

Vismodegib for periocular and orbital basal cell carcinoma.

Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ.

JAMA Ophthalmol. 2013 Dec;131(12):1591-4. doi: 10.1001/jamaophthalmol.2013.5018.

PMID:
24136169
4.

Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.

Demirci H, Worden F, Nelson CC, Elner VM, Kahana A.

Ophthal Plast Reconstr Surg. 2015 Nov-Dec;31(6):463-6. doi: 10.1097/IOP.0000000000000388.

5.

Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.

Yin VT, Pfeiffer ML, Esmaeli B.

Ophthal Plast Reconstr Surg. 2013 Mar-Apr;29(2):87-92. doi: 10.1097/IOP.0b013e3182831bf3. Review.

6.

Vismodegib in advanced basal-cell carcinoma.

Babacan T, Sarici F, Altundag K.

N Engl J Med. 2012 Sep 6;367(10):969-70; author reply 970. doi: 10.1056/NEJMc1208003#SA1. No abstract available.

PMID:
22931270
7.

Vismodegib in advanced basal-cell carcinoma.

Henkin RI.

N Engl J Med. 2012 Sep 6;367(10):970; author reply 970-1. doi: 10.1056/NEJMc1208003#SA2. No abstract available.

PMID:
22931271
8.

Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.

Kahana A, Worden FP, Elner VM.

JAMA Ophthalmol. 2013 Oct;131(10):1364-6. doi: 10.1001/jamaophthalmol.2013.4430. No abstract available.

9.

Vismodegib granted FDA approval for treatment of basal cell carcinoma.

[No authors listed]

Oncology (Williston Park). 2012 Feb;26(2):174, 213. No abstract available.

10.

Vismodegib (Erivedge) for basal cell carcinoma.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4. No abstract available.

PMID:
22777303
11.

Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.

Wilkes GM.

Oncology (Williston Park). 2012 Aug;26(8 Suppl Nurse Ed):31-3. No abstract available.

PMID:
25375009
12.

[Vismodegib in metastasized basal cell carcinoma].

Reinders MG, Dirix L, Mosterd K, van Doorn R.

Ned Tijdschr Geneeskd. 2013;157(12):A6011. Dutch.

PMID:
23515044
13.

Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.

Kaehler KC, Gutzmer R, Egberts F, Hauschild A.

J Dtsch Dermatol Ges. 2014 Oct;12(10):906-7. doi: 10.1111/ddg.12342. No abstract available.

PMID:
25041591
14.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
15.

Oral hedgehog-pathway inhibitors for basal-cell carcinoma.

Lear JT.

N Engl J Med. 2012 Jun 7;366(23):2225-6. doi: 10.1056/NEJMe1202170. No abstract available.

PMID:
22670909
16.

Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.

Iarrobino A, Messina JL, Kudchadkar R, Sondak VK.

J Am Acad Dermatol. 2013 Jul;69(1):e33-4. doi: 10.1016/j.jaad.2013.01.023. No abstract available.

PMID:
23768306
17.

Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.

Orouji A, Goerdt S, Utikal J, Leverkus M.

Br J Dermatol. 2014 Aug;171(2):431-3. doi: 10.1111/bjd.12840. No abstract available.

PMID:
24446722
18.

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA.

Future Oncol. 2015;11(9):1429-35. doi: 10.2217/fon.15.20. Review.

PMID:
25952787
19.

Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

Lyseng-Williamson KA, Keating GM.

Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.

PMID:
23329081
20.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ.

J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012.

Items per page

Supplemental Content

Support Center